Conference
Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial
Abstract
Abstract
Authors
Ferrannini G; Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Dyal L; Lakshmanan M; Mellbin L; Probstfield J; Riddle MC
Volume
41
Publisher
Oxford University Press (OUP)
Publication Date
November 1, 2020
DOI
10.1093/ehjci/ehaa946.3353
Conference proceedings
European Heart Journal
Issue
Supplement_2
ISSN
0195-668X